Amgen Testing Whether Different Is Better In Obesity, With Data Due This Year

GIP Receptor Antagonism Versus Agonism On Trial

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Amgen’s obesity drug MariTide will not have Phase II results until late 2024, but the company’s Q4 earnings call was dominated by questions seeking insight about the drug’s potential.

Weight scale instrument for measurement balance of people body concept
Amgen's Phase II MariTide data are expected in late 2024 • Source: Shutterstock

Amgen, Inc. has taken a divergent path with its obesity drug candidate maridebart cafraglutide (MariTide, AMG 133), a GLP-1 agonist and GIP receptor (GIPR) antagonist, which has delivered intriguing weight loss in a Phase I clinical trial despite differing from Eli Lilly and Company’s Zepbound (tirzepatide), which agonizes both GLP-1 and GIP. Phase II data for MariTide are not expected until late 2024, leaving observers impatient for data clarifying Amgen’s approach.

Key Takeaways

  • Amgen’s Q4 earnings call was dominated by questions about the company’s maridebart cafraglutide (MariTide, AMG 133), a GLP-1 agonist and GIP receptor (GIPR) antagonist.

While Amgen announced a 20% increase in Q4 revenue to $8.2bn, thanks to the closing of its $27.8bn acquisition of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D